Lysyl Oxidase and Lysyl Hydroxylase Levels in Knee Osteoarthritis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Source: NCT07875296, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Afyonkarahisar Health Sciences University
- Trial code
- NCT07875296
- Record updated
- 15 October 2026
- Original description
The aim of this study is to investigate the serum levels of lysyl hydroxylase, lysyl oxidase, and the lysyl oxidase-like enzymes in patients with different stages of knee osteoarthritis and to compare these findings with those of healthy control subjects.Read full original descriptionShow less
Lysyl Oxidase and Lysyl Hydroxylase Levels in Patients With Knee Osteoarthritis
The aim of this study is to investigate the serum levels of lysyl hydroxylase, lysyl oxidase, and the lysyl oxidase-like enzymes in patients with different stages of knee osteoarthritis and to compare these findings with those of healthy control subjects.
Inclusion: Female participants aged between 40 and 70 years; Diagnosed with knee osteoarthritis according to clinical and radiographic criteria, and presenting to the Department of Physical Medicine and Rehabilitation, Afyonkarahisar Health Sciences University (AFSU); Body Mass Index (BMI) between 18.5 and 40 kg/m².
Exclusion: History of previous knee surgery; Any inflammatory arthritis or other rheumatologic disease with related signs or symptoms; History of knee trauma involving cruciate ligaments or menisci within the past 3 months; Secondary osteoarthritis due to other joint disorders such as septic arthritis, avascular necrosis, or Paget's disease; Presence of metabolic diseases or severe comorbidities, including uncontrolled diabetes mellitus, chronic kidney disease (GFR < 60 mL/min/1.73 m²), liver failure, malignancy, severe cardiovascular disease, chronic respiratory disorders, or chronic intestinal diseases; Recent intra-articular injection to the knee joint within the last 3 months.